Towards rational psychotropic-prescribing for people with learning disability

British Journal of Learning Disabilities

Volumn 25, Issue 2, 1997, Pages 46-52

  Clarke, David J ^a  

^a QUEEN ELIZABETH PSYCHIATRIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001804363     PISSN: 13544187     EISSN: 14683156     Source Type: Journal    
DOI: 10.1111/j.1468-3156.1997.tb00009.x     Document Type: Review

References (50)

1. Aman, M. G. (1987) Overview of pharmacotherapy: Current status and future directions. Journal of Mental Deficiency Research 31, 121-30.
2. Aman, M. G., Singh, N. N., Stewart, A.W. and Field, C. J. (1985) The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 91,485-91.
3. Anderson, J. and Adams, C. (1996) Family interventions in schizophrenia: An effective but underused treatment. British Medical Journal 313,505-6.
4. Blackbum, I. M., Bishop, S., Glen, A. I. M., Whalley, L. J. and Christie, J. E. (1981) The efficacy of cognitive therapy on depression: A treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. British Journal of Psychiatry 139, 181-9.
5. Branford, D. (1994) A study of prescribing for people with learning disabilities living in the community and in National Health Service care. Journal of Intellectual Disability Research 38,577436.
6. Briggs, R. (1989) Monitoring and evaluating psychotropic drug use for persons with mental retardation: A follow-up report. American Journal on Mental Retardation 93,618-23.
7. Buck, J. A. and Sprague, R. L. (1989) Psychotropic medication of mentally retarded residents in community long-term care facilities. American Journal on Mental Retardation 93, 618-23.
8. Clarke, D. J. (1989) Antilibidinal drugs and mental retardation: A review. Medicine, Science and the Law 29, 136-46.
9. Clarke, D. J. (1997) Physical treatments. In S. Read (ed.) Learning Disability Psychiatry. London: Saunders. (In press.)
10. Clarke, D. J., Kelley, S., Thinn, K. and Corbett, J. A. (1990) Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. Journal of Mental Deficiency Research 34,385-95.
11. Clarke, D. J. and Pickles, J. K. (1994) Lithium treatment for people with learning disability: Patients' and carers' knowledge of hazards and attitudes to treatment. Journal of Intellectual Disability Research 38, 187-94.
12. Cole, J., Merman, C. L. and Goldberg, S. C. (1964) Phenothiazine treatment of acute schizophrenia. Archives of General Psychiatry 10,246451.
13. Davis, J. M. and Garver, D. L. (1978) Neuroleptics: Clinical use in psychiatry. In L. L. Iversen and S. D. Iversen (eds) Handbook of Psychopharmacology. Vol. 10. Neuroleptics and Schizophrenia. New York: Plenum Press.
14. Einfeld, S. L. (1990) Guidelines for the use of psychotropic meditation in individuals with developmental disabilities. Australia and New Zealand Journal of Developmental Disabilities 16, 71-3.
15. Ereshefsky, L., Watanabe, M. D. and Tran-Johnson, T. K. (1989) Clozapine: An atypical antipsychotic agent,. Clinical Pharmacology 8,691-709.
16. Fleming, I., Caine, A., Ahmed, S. and Smith, S. (1996) Aspects of the use of psychoactive medication among people with intellectual disabilities who have been resettled from long-stay hospitals into dispersed housing. Journal of Applied Research in Intellectual Disabilities 9, 194-205.
17. Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D. and Rapoport, J. L. (1993) A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry 50,
18. Hill, B. K., Balow, E. A. and Bruininks, R. H. (1985) A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacology Bulletin 21,279-84.
19. Inoue, F. (1982) A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons. Mental Retardafion 20, 70-4.
20. Intagliata, J. and Rinck, C. (1985) Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacology Bulletin 21,268-78.
21. International Consensus Panel on Psychotropic Medication (1996) Guidelines For The Use Of Psychotropic Medication. Edited Revision, April 1996. Ohio: Nisonger Centre.
22. Kiernan, C., Reeves, D. and Alborez, A. (1995) The use of antipsychotic drugs with adults with learning disabilities and challenging behaviour. Journal of Intellectual Disability Research 39,263-74.
23. Lewis, M. H., Bodfish, J. W., Powell, S. B. and Golden, R. N. (1995) Clomipramine treatment for stereotypy and related repetitive movement disorders associated with mental retardation. American Journal on Mental Retardation 100,299-312.
24. Lewis, M. H., Bodfish, J. W., Powell, S. B., Parker, D. E. and Golden, R. N. (1996) Clomipramine treatment for selfinjurious behavior of individuals with mental retardation: A double-blind comparison with placebo. American Journal on Mental Retardation 100,654-65.
25. Lipman, R. S. (1970) The use of psychopharmacological agents in residential facilities for the retarded. In E J. Menolascino (ed.) Psychiatric Approaches to Mental Retardation. New York: Basic Books.
26. Lloyd, K. C., Hornykiewics, 0. and Davidson, L. (1981) Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. New England Journal of Medicine 305, 1106-11.
27. Manchester, D. (1993) Neuroleptics, learning disability, and the community: Some history and mystery. British Medical Journal 307,184-7.
28. Marshburn, E. C. and Aman, M. G. (1992) Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of Autism and Developmental Disorders 22,357-73.
29. Matson, J. L. and Schroeder, S. R. (1988) Editorial: A retraction. Research in Developmental Disabilities 9, 1-2.
30. Mouchka, S. (1985) Issues in psychopharmacology with the mentally retarded. Psychopharmacology Bulletin 21,262-7.
31. Nelson, H. E., Thrasher, S. and Barnes, T, R. E. (1991) Practical ways of alleviating auditory hallucinations. British Medical Journal 302,327.
32. Poindexter, A. R. (1989) Psychotropic drug patterns in a large ICF/MR facility: A ten-year experience. American Journal on Mental Retardation 93,624-6.
33. Lipman, R. S. (1970) The use of psychopharmacological agents in residential facilities for the retarded. In E J. Menolascino (ed.) Psychiatric Approaches to Mental Retardation. New York: Basic Books.
34. Lloyd, K. C., Hornykiewics, 0. and Davidson, L. (1981) Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. New England Journal of Medicine 305, 1106-11.
35. Manchester, D. (1993) Neuroleptics, learning disability, and the community: Some history and mystery. British Medical Journal 307,184-7.
36. Marshburn, E. C. and Aman, M. G. (1992) Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of Autism and Developmental Disorders 22,357-73.
37. Matson, J. L. and Schroeder, S. R. (1988) Editorial: A retraction. Research in Developmental Disabilities 9, 1-2.
38. Mouchka, S. (1985) Issues in psychopharmacology with the mentally retarded. Psychopharmacology Bulletin 21,262-7.
39. Nelson, H. E., Thrasher, S. and Barnes, T, R. E. (1991) Practical ways of alleviating auditory hallucinations. British Medical Journal 302,327.
40. Poindexter, A. R. (1989) Psychotropic drug patterns in a large ICF/MR facility: A ten-year experience. American Journal on Mental Retardation 93,624-6.
41. Rinck, C., Guidry, J. and Calkins, C. F. (1989) Review of states' practices on the use of psychotropic medication. American Journal on Mental Retardation 93,657-68.
42. Rosenthal, N. E., Sack, D. A., Carpenter, C. J., Parry, B. L., Mendelson, W. B. and Wehr, T. A. (1985) Antidepressant effects of light in seasonal affective disorder. American Journal of Psychiat y 142, 163-70.
43. Sandman, C. A. and Hetrick, W. P. (1995) Opiate mechanisms in self-injury. Mental Retardation and Developmental Disabilities Research Reviews 1, 13M.
44. Schroeder, S. R., Hammock, R. G., Mulick, J. A., Rojahn, J., Walson, P., Fernald, W., Meinhold, P. and Saphare, G. (1995) Clinical trials of D1 and D2 dopamine modulating drugs and self-injury in mental retardation and developmental disability. Mental Retardation and Developmental Disability Research Reviews 1,120-9.
45. Silva, D. A. (1979) The use of medication in a residential institution for mentally retarded persons. Mental Retardation 17, 285-8.
46. Sprague, R. L. and Werry, J. S. (1971) Methodology of psychopharmacological studies with the retarded. In N. R. Ellis (ed.) International Review of Research in Mental Retardation. New York: Academic Press.
47. Stone, R. K., Alvarez, W. F., Ellman, G., Hom, A. C. and White, J. F. (1989) Prevalence and prediction of psychotropic drug use in California developmental centers. American Journal on Mental Retardation 93, 627-32.
48. Sturmey, P., Reed, J. and Corbett, J. (1991) Psychometric assessment of psychiatric disorders in people with learning difficulties (mental handicap): A review of measures. Psychological Medicine 21,143-55.
49. Thinn, K,., Clarke, D. J. and Corbett, J. A. (1990) Psychotropic drugs and mental retardation: 2. A comparison of psychoactive drug use before and after discharge from hospital to community. Journal of Mental Deficiency Research 34,397-407.
50. Thompson, T., Egli, M., Symon, F. and Delaney, D. (1994) Neurobehavioral mechanisms of drug action in developmental disabilities. In T. Thompson and D. B. Gray (eds) Destructive Behavior in Developmental Disabilities (pp. 133-80). Thousand Oaks: Sage